Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2026
Combined treatment of intestinal dysbiosis in patients with chronic Hepatitis C on the background of obesity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Derbak Mariya A, Vorobets Vira V, Dankanych Yevheniia E, Sitkar Andrii D, Horlenko Olesya M, Krasnova Anatolija A, Bletskan Myroslava M
Аннотация
OBJECTIVE: Aim: To study the effectiveness of ursodeoxycholic acid use in the combined treatment of intestinal dysbiosis in patients with chronic Hepatitis C associated with obesity.
PATIENTS AND METHODS: Materials and Methods: 84 patients with CHC were examined. All patients underwent a microbiological study of stool, the levels of cytokine profile indicators were determined and the psychological status and the quality of life were assessed. Two groups were formed: 1 gr (n=40) - received LA-5 and BB-12 1 gtt. X TID and 2 gr (n=44) - LA-5 + BB-12 + UDCA 500 mg qhs for 1 month.
RESULTS: Results: As a result of simultaneous administration of LA-5 + BB-12 + UDCA in the above-mentioned doses, in 93.2% of patients with CHC an normalization of the act of defecation and the disappearance of symptoms of intestinal dysbiosis were found. In patients taking only LA-5 and BB-12, the above-mentioned positive changes were observed in 62.5%.
CONCLUSION: Conclusions: It was found that the additional prescription of UDCA in combination with a probiotic not only contributes to the restoration of colon microbiocenosis, but also improves the course of CHС, and increases the quality of life of patients.
PATIENTS AND METHODS: Materials and Methods: 84 patients with CHC were examined. All patients underwent a microbiological study of stool, the levels of cytokine profile indicators were determined and the psychological status and the quality of life were assessed. Two groups were formed: 1 gr (n=40) - received LA-5 and BB-12 1 gtt. X TID and 2 gr (n=44) - LA-5 + BB-12 + UDCA 500 mg qhs for 1 month.
RESULTS: Results: As a result of simultaneous administration of LA-5 + BB-12 + UDCA in the above-mentioned doses, in 93.2% of patients with CHC an normalization of the act of defecation and the disappearance of symptoms of intestinal dysbiosis were found. In patients taking only LA-5 and BB-12, the above-mentioned positive changes were observed in 62.5%.
CONCLUSION: Conclusions: It was found that the additional prescription of UDCA in combination with a probiotic not only contributes to the restoration of colon microbiocenosis, but also improves the course of CHС, and increases the quality of life of patients.